Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Firebrick Pharma Limited (AU:FRE)
ASX:FRE
RESEARCH TOOLSreports
Holding AU:FRE?
Track your performance easily
FRE Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.05 - AU$0.11
Previous CloseAU$0.06
Volume4.00K
Average Volume (3M)66.37K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)AU$7.14M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.92
Next Earnings
Feb 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares OutstandingN/A
10 Day Avg. Volume53,594
30 Day Avg. Volume66,372
Standard Deviation0.27
R-Squared0.06
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)5509.52
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Firebrick Pharma Limited News
PremiumCompany Announcements
Firebrick Pharma Issues 1.5 Million Unquoted Options
PremiumCompany Announcements
Firebrick Pharma Unveils New Securities Issue
PremiumCompany Announcements
Firebrick Pharma Extends Agreement to Boost Asian Sales
PremiumCompany Announcements
Firebrick Pharma’s AGM Success and Innovation Highlight
PremiumCompany Announcements
Firebrick Pharma Expands Nasodine Marketing in Singapore
PremiumCompany Announcements
Firebrick Pharma to Host Virtual AGM for ShareholdersPremiumCompany Announcements
Firebrick Pharma’s Strategic Moves Boost Market PositionPremiumCompany Announcements
Firebrick Pharma Lists New Securities on ASXOptions Prices
Currently, No data available
---
Ownership Overview
FRE FAQ
What was Firebrick Pharma Limited’s price range in the past 12 months?
Firebrick Pharma Limited lowest share price was AU$0.04 and its highest was AU$0.11 in the past 12 months.
What is Firebrick Pharma Limited’s market cap?
Currently, no data Available
When is Firebrick Pharma Limited’s upcoming earnings report date?
Firebrick Pharma Limited’s upcoming earnings report date is Feb 07, 2025 which is in 46 days.
How were Firebrick Pharma Limited’s earnings last quarter?
Firebrick Pharma Limited released its earnings results on Aug 30, 2024. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is Firebrick Pharma Limited overvalued?
According to Wall Street analysts Firebrick Pharma Limited’s price is currently Overvalued.
Does Firebrick Pharma Limited pay dividends?
Firebrick Pharma Limited does not currently pay dividends.
What is Firebrick Pharma Limited’s EPS estimate?
Firebrick Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Firebrick Pharma Limited have?
Firebrick Pharma Limited has 210,108,500 shares outstanding.
What happened to Firebrick Pharma Limited’s price movement after its last earnings report?
Firebrick Pharma Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Firebrick Pharma Limited?
Currently, no hedge funds are holding shares in AU:FRE
---
Firebrick Pharma Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:FRE Sentiment 90%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth AU$35.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.00%
12-Months-Change
Fundamentals
Return on Equity
-51.22%
Trailing 12-Months
Asset Growth
-19.32%
Trailing 12-Months
Company Description
Firebrick Pharma Limited
Firebrick Pharma Ltd is an Australian pharmaceutical developer. The company has developed a nasal spray medicine that targets the viral cause of the common cold.
---
Technical Analysis
IDT Australia Limited
―
PYC Therapeutics Limited
―
LBT Innovations Limited
―
Invex Therapeutics Ltd.
―
---